Pathfinder Cell Therapy's net tangible assets is $-6.7M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2015), PFND shows a net tangible assets of $-6.7M. That compares with $-5.7M in the prior-year period — down 19.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, PFND's net tangible assets is now $-6.7M (was $-5.7M) — a 19.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Pathfinder Cell Therapy is outperforming or lagging.
Tracking PFND's net tangible assets over time shows whether Pathfinder Cell Therapy is scaling, shrinking, or reshaping that part of the business. The current reading is $-6.7M That compares with $-5.7M in the prior-year period — down 19.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net tangible assets page, Stockcircle has Pathfinder Cell Therapy's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $-6.7M) with ownership activity and broader fundamentals.
Pathfinder Cell Therapy's net tangible assets is $-6.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.